ATL1103 / COR-004
Released
Released
Announcement PDF
ATL1103/COR-004
In relation to Antisense Therapeutics Limited’s (“ANP” or “the Company”) ASX
announcement yesterday regarding ANP’s licensing partner Cortendo’s Form 1 Registration
Statement Prospectus (Prospectus), and for ease of reference, the Company provides
Schedule 2 of Exhibit 10 of the Prospectus relating to the ATL1103/COR-004 executed
Technology License Agreement.
ANP notes the following milestone events as:
−
Start of the first Phase III Trial for ATL1103/COR-004 for the first Acromegaly
Indication in any jurisdiction outside Australia & New Zealand;
−
Filing of New Drug Application in the U.S. for ATL1103/COR-004 for the first
Acromegaly Indication;
−
Filing of Marketing Approval Application in the European Union for ATL1103/COR-004
for the first Acromegaly Indication;
−
US Approval (excluding Pricing Approval) for ATL1103/COR-004 for the first
Acromegaly Indication;
−
EU Approval (excluding Pricing Approval) for ATL1103/COR-004 for the first
Acromegaly Indication; and
−
Japanese Approval (excluding Pricing Approval) for ATL1103/COR-004 for the first
Acromegaly Indication.
In addition, ANP is entitled to receive further payments based on achievement of the above
milestones for a second indication in Acromegaly and/or with respect to any other
endocrinology indication. There are also commercial milestones based on sales performance
targets with respect to the first acromegaly indication. These payments in total would add up
to US$124Million (A$177Million) if milestones are successfully achieved.
The Company would also like to confirm that the Milestone Shares Subscription as part of
the potential milestone fees relating to the Start of the first Phase III Trial for an ATL1103
Product for the first Acromegaly Indication, which is referred to in Schedule 2, is a one off
purchase of US$1M in ANP equity by Cortendo.
Furthermore, upon regulatory approval of ATL1103/COR-004 and achievement of sales
performance targets, ANP would be entitled to royalty payments based on a percentage,
ranging from the mid-single digits to the mid-teens, of net sales of ATL1103/COR-004.
Contact Information:
Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999
About Antisense Therapeutics Limited
Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development
company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for
large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed
from Isis Pharmaceuticals Inc. (ISIS), a world leader in antisense drug development and commercialisation ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing
the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug
designed to block GHr production which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in
patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a
potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being
investigated as a potential treatment for cancer.
6 WALLACE AVENUE, TOORAK VIC 3142 AUSTRALIA
TEL . +61 (3) 9827 8999 FAX +61 (3) 9827 1166 WEB WWW.ANTISENSE.COM.AU
ANTISENSE THERAPEUTICS LIMITED ABN 41 095 060 745
Cortendo AB (Form: F-1, Received: 08/28/2015 16:39:47)
Page 412 of 596
This agreement (together with all Schedules to this agreement) constitutes the entire agreement between the parties in
connection with its subject matter and supersedes all previous agreements or understandings between the parties in
connection with its subject matter, including the Non-Disclosure Agreement.
66
Schedule 1- Technology
[****]
67
Schedule 2 — Milestones
1.
Clinical and Regulatory Milestones 1
Milestone
WITH RESPECT TO THE FIRST ACROMEGALY INDICATION
Start of the first Phase III Trial for an ATL1103
Product for the first Acromegaly Indication in any
jurisdiction in the Territory
Filing of an NDA in the U.S. for an ATL1103
Product for the first Acromegaly Indication
Filing of an MAA in the EU:
If In-Human Trial Milestone
was a Phase III Trial
US$[****], comprising:
Milestone Fee
If In-Human Trial Milestone
was a Phase II B Trial
US$[****]
- $US[****] to be paid in
accordance with clause 9.6; and
- the Milestone Shares Subscription
Price to be paid in accordance with
clause 10.3
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
(a) through the centralized procedure; or
(b) in at least 3 of the 5 major markets in the EU
comprised of the United Kingdom, France,
Germany, Italy or Spain); or
(c) the date that is six calendar months after filing in
at least 1 of the one of the following countries; the
United Kingdom, France, Germany, Italy or Spain,
whichever occurs first, for an ATL1103 Product for
the first Acromegaly Indication
US Approval (excluding Pricing Approval) for an
ATL1103 Product for the first Acromegaly
Indication
EU Approval (excluding Pricing Approval) for an
ATL1103 Product for the first Acromegaly
Indication
Japanese Approval (excluding Pricing Approval) for
an ATL1103 Product for the first Acromegaly
Indication
For the avoidance of doubt, if the In-Human Trial Milestone is a Phase III Trial, then the Milestone Fees in the second
column of the above table apply and the third column of the above table no longer has any application or relevance under this
agreement.
1
68
Milestone
Milestone Fee
file:///C:/Users/mdiamond/AppData/Local/Microsoft/Windows/Temporary%20Internet... 3/09/2015
Cortendo AB (Form: F-1, Received: 08/28/2015 16:39:47)
Page 413 of 596
WITH RESPECT TO THE SECOND ACROMEGALY INDICATION
Start of a Phase III Trial for an ATL1103 Product for
the second Acromegaly Indication in any jurisdiction
in the Territory
Filing of an NDA in the U.S. for an ATL1103
Product for the second Acromegaly Indication
Filing of an MAA in the EU:
If In-Human Trial Milestone
was a Phase III Trial
If In-Human Trial Milestone
was a Further Phase II B Trial
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
(a) through the centralized procedure; or
(b) in at least 3 of the 5 major markets in the EU
comprised of the United Kingdom, France,
Germany, Italy or Spain); or
(c) the date that is six calendar months after filing in
at least 1 of the one of the following countries; the
United Kingdom, France, Germany, Italy or Spain,
whichever occurs first, for an ATL1103 Product for
the second Acromegaly Indication
U.S. Approval (excluding Pricing Approval) for an
ATL1103 Product for the second Acromegaly
Indication
EU Approval (excluding Pricing Approval) for an
ATL1103 Product for the second Acromegaly
Indication
Milestone
Milestone Fee
WITH RESPECT TO ANY OTHER INDICATION
Start of a Phase III Trial for an ATL1103 Product for any Other
Indication in any jurisdiction in the Territory
Filing of an NDA in the U.S. for an ATL1103 Product for any
Other Indication
Filing of an MAA in the EU for an ATL1103 Product for any
Other Indication
U.S. Approval (excluding Pricing Approval) for an ATL1103
Product for any Other Indication
EU Approval (excluding Pricing Approval) for an ATL1103
Product for any Other Indication
Japanese Approval (excluding Pricing Approval) for an ATL1103
Product for any Other Indication
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
US$[****]
69
2.
Commercial Milestones 2
Milestone
WITH RESPECT TO THE FIRST ACROMEGALY INDICATION
Aggregate Net Sales in a Calendar Year of
US$[****]
Aggregate Net Sales in a Calendar Year of
US$[****]
Aggregate Net Sales in a Calendar Year of
US$[****]
Aggregate Net Sales in a Calendar Year of
US$[****]
Aggregate Net Sales in a Calendar Year of
US$[****]
If In-Human Trial Milestone
was a Phase III Trial
US$[****]
(once off)
US$[****]
(once off)
US$[****]
(once off)
US$[****]
(once off)
US$[****]
(once off)
Milestone Fee
If In-Human Trial Milestone
was a Further Phase II B Trial
US$[****]
(once off)
US$[****]
(once off)
US$[****]
(once off)
US$[****]
(once off)
US$[****]
(once off)
file:///C:/Users/mdiamond/AppData/Local/Microsoft/Windows/Temporary%20Internet... 3/09/2015
Cortendo AB (Form: F-1, Received: 08/28/2015 16:39:47)
Page 414 of 596
For the avoidance of doubt, (i) if the In-Human Trial Milestone is a Phase III Trial, then the Milestone Fees in the second
column of the above table apply and the third column of the above table no longer has any application or relevance under this
agreement; and (ii) each of the Commercial Milestone Fees shall be paid only one time, upon the first achievement of such
event in any Calendar Year.
2
70
Schedule 3 — ATL1103 higher dose study
A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult
Patients with Acromegaly
Budget
$ (AUD)
Clinical Monitoring, Data Management & CSR
Site costs / StV & PARC
Shipping
Central Lab assays
IMP, Storage, shipping & labelling
Medical Monitoring & DSMB
Additional Stability/ref standard
PK & Complement
MRI & central reader
Out of scope
Travel
TOTAL
$
[****]
[****]
[****]
[****]
[****]
[****]
[****]
[****]
[****]
[****]
[****]
[****]
71
TRIAL OUTLINE
Study Title:
A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of
ATL1103 300mg in Adult Patients with Acromegaly.
Protocol Number:
1103-CT03
Test Drug:
ATL1103
Route of Administration:
Subcutaneous
Indication:
Acromegaly
Study Sponsor:
Antisense Therapeutics Limited
6 Wallace Avenue
Toorak Victoria 3142
Australia
Telephone +61 3 9827 8999
Protocol Version:
2.0
Date:
11 December 2014
CONFIDENTIALITY STATEMENT
All information relating to the study drug, Investigator’s Brochure, Clinical Protocol, Case Report Forms and any information
and results developed during, or arising from the study, is considered confidential and proprietary information of Antisense
file:///C:/Users/mdiamond/AppData/Local/Microsoft/Windows/Temporary%20Internet... 3/09/2015
Share your feedback
Discover